Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on November 4, 2026, a projected date rather than a confirmed one. There are 4 upcoming events on record.
Cash runway is approximately 100.2 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 4, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| February 3, 2028 | A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures | Trial Milestone | Phase 2 |
| July 15, 2029 | Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures | Trial Milestone | Phase 3 |
| July 15, 2029 | Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1 | Trial Milestone | Phase 3 |
Track RAPP alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open RAPP in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.